Bio-Matrix Scientific Group

Bio-Matrix Scientific Group, Inc. engages in the development of regenerative medicine applications through its subsidiary, Regen BioPharma, Inc. The company focuses on licensing from other entities until the successful completion of Phase I and Phase II clinical trials, after which it intends to sell or license the developed applications or advance them further into Phase III clinical trials. Its products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, and small molecules. The company is dedicated to the development of HemaXellerate I, a cell therapy designed to treat damaged bone marrow. HemaXellerate II is expected to become a universal donor endothelial cell therapy. dCellVax is a therapy that extracts dendritic cells from cancer patients. Tcellvax is anticipated to be an autologous cell product. The company identifies small molecules through high-throughput screening processes.